Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Patients with heart failure (HF) syndromes have been categorized as those with reduced ejection fraction (EF) or preserved EF (HFpEF), and ischemia plays a key role in both types. HF remains a major cause of morbidity and mortality worldwide, and with the aging of our population this burden continues to rise, predominantly as a result of hospitalizations for HFpEF. Patients with obstructive coronary artery disease more likely have HF with reduced EF, rather than HFpEF, secondary to acute ischemic injury resulting in myocardial infarction, and large outcomes trials of treatments with neurohumoral inhibition have documented reduced adverse outcomes. In contrast, similar treatments in patients with HFpEF have not proven beneficial. This therapeutic dilemma may be attributed, in part, to heterogeneity in the underlying pathophysiology with different systemic and myocardial signaling pathways, despite similar clinical presentations and findings, in patients with HFpEF. Also, emerging evidence indicates that impaired myocardial perfusion and inflammation secondary to multiple comorbidities are key mechanisms in HFpEF. We will thoroughly review the role of ischemic heart disease in the pathogenesis of HF with reduced EF and HFpEF, and discuss the medical management strategies available for these conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · cited 1×
“Reduction in mortality and morbidity with spironolactone was also seen in a large, randomized placebocontrol trial, where the majority of the patients had HFrEF secondary to ischemic cardiomyopathy.(58) The HF guidelines give a Class I, Level of Evidence A recommendation for use of Table 2.”
BackgroundHeart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“talizations among subjects with type 2 diabetes mellitus and at high risk for cardiovascular events.(125,126) This benefit was ob-”
BackgroundAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Carson, P., DiCarlo, L., DeMets, D., White, B. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032423 · Cited by 5,812
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Cardiac Resynchronization in Chronic Heart Failure
Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013168 · Cited by 4,648
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Advanced heart failure treated with continuous-flow left ventricular assist device
Slaughter, M. S., Rogers, J. G., Milano, C. A., Russell, S. D., Conte, J. V., Feldman, D., Sun, B., Tatooles, A. J., Delgado, R. M., Long, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0909938 · Cited by 3,063
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809 · cited 1×
“Function HF With an Aldosterone Antagonist), a placebo-controlled trial of 3445 patients.(130) The main trial showed a nonsig-”
BackgroundIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 3×
“Thus, continued use of a classification based on EF alone may be insufficient.8 Nearly 70% of all HF syndromes can be attributed to underlying IHD.9 Despite efforts to address the key prevention risk factors for IHD, the incidence of HF hospitalizations has not largely changed and is actually projected to rise.4 Ische…”
MethodInfluentialPfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101 · cited 1×
“In addition, several small randomized trials have shown that compliance with continuous positive airway pressure in patients with obstructive sleep apnea and HF is recommended to improve daytime sleepiness, nocturnal oxygenation, and functional status in patients with HF(103,104); however, these trials failed to show…”
BackgroundIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960 · cited 1×
“In the I-PRESERVE trial (Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction) of 4128 patients with HFpEF, irbesartan failed to reduce cardiovascular death or hospitalization for a cardiovascular cause compared with placebo.(119) These findings were consistent in CHARM-Preserved (Candesartan in H…”
ResultCombination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487 · cited 9×
“However, the CORONA (Controlled Rosuvastatin Multinational Trial in HF) compared rosuvastatin versus placebo in patients with ischemic cardiomyopathy and HFrEF.(95) At 33 months (median follow-up), rosuvastatin, compared with placebo, did not reduce the primary outcome, a composite of nonfatal MI, nonfatal stroke, and…”
ResultInfluentialGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Angiotensin-neprilysin inhibition in acute decompensated heart failure
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812851 · Cited by 1,260
Continuous Positive Airway Pressure for Central Sleep Apnea and Heart Failure
Bradley, T. D., Logan, A. G., Kimoff, R. J., Sériès, F., Morrison, D., Ferguson, K., Belenkie, I., Pfeifer, M., Fleetham, J., Hanly, P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051001 · Cited by 1,189
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179 · cited 1×
“enhanced renal tubular sodium reabsorption resulting in an expanded plasma volume.(114) Adipocytes exert an inflammatory”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Fox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789
Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754 · cited 1×
“These findings are in line with the HF subgroups of the COMPASS (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) and ATLAS ACS 2-TIMI 51 (Trial of Rivaroxaban in Patients with Recent Acute Coronary Syndrome; the data regarding EF were not reported in both trials) which also s…”
ResultBrutsaert, D. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00017.2002 · Cited by 697 · cited 1×
“The reduction in cGMP is associated with endothelial dysfunction, microvascular disease, and myocardial dysfunction.(70) Established neuro-hormonal inhibitory therapies do not target this pathway.”
BackgroundShindler, D. M., Kostis, J. B., Yusuf, S., Quinones, M. A., Pitt, B., Stewart, D., Pinkett, T., Ghali, J. K., Wilson, A. C., & The SOLVD Investigators (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89163-1 · Cited by 516 · cited 9×
“A subgroup analysis from the Scandinavian multicenter study showed that over a 5-year follow-up, simvastatin (compared with placebo) was associated with reduction in HF (8.3% versus 10.3%, P 0.015).93 Data from retrospective analyses and observational studies continued to suggest a beneficial role of statins in HF pat…”
BackgroundInfluentialInflammatory Markers and Incident Heart Failure Risk in Older Adults
Kalogeropoulos, A., Georgiopoulou, V., Psaty, B. M., Rodondi, N., Smith, A. L., Harrison, D. G., Liu, Y., Hoffmann, U., Bauer, D. C., Newman, A. B., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.045 · Cited by 478
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K. (1997) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(97)90022-1 · Cited by 386 · cited 1×
“015).(93) Data from retrospective analyses and observational studies continued to suggest a beneficial role of statins in HF patients.”
BackgroundRivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
Zannad, F., Anker, S. D., Byra, W. M., Cleland, J. G. F., Fu, M., Gheorghiade, M., Lam, C. S. P., Mehra, M. R., Neaton, J. D., Nessel, C. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808848 · Cited by 345 · cited 1×
“5 mg twice daily) versus placebo, showed that rivaroxaban was not associated with a lower rate of death, MI, or stroke compared with placebo.(86) However, a post hoc analysis of this trial showed that low dose rivaroxaban might be associated with a lower risk of thromboembolic events, namely the composite of MI or str…”
ResultSuleiman, M., Khatib, R., Agmon, Y., Mahamid, R., Boulos, M., Kapeliovich, M., Levy, Y., Beyar, R., Markiewicz, W., Hammerman, H., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.055 · Cited by 264
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242 · cited 11×
“Additionally, the guidelines also recommend management of iron deficiency anemia as well as sleep disorders in patients with New York Heart Association class II–IV HF.50 Treatment with iron supplementation in patients with iron deficiency anemia has been shown to improve the functional capacity, quality of life, and m…”
BackgroundInfluentialCardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236 · cited 1×
“hibition of glucose reabsorption in the proximal renal tubules, and hence reduction of the plasma volume.(128,129) An ongoing”
BackgroundObesity-Related Heart Failure With a Preserved Ejection Fraction
Packer, M., & Kitzman, D. W. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.01.009 · Cited by 172
The Funny Current: Cellular Basis for the Control of Heart Rate
DiFrancesco, D., & Borer, J. S. (2007) · Drugs · doi:10.2165/00003495-200767002-00003 · Cited by 155 · cited 1×
“The primary advantage of ivabradine over β-blocker therapy is a lack of negative inotropism.(76) The ivabradine and outcomes”
BackgroundAbuzaid, A. S., Al Ashry, H. S., Elbadawi, A., Ld, H., Saad, M., Elgendy, I. Y., Elgendy, A., Mahmoud, A. N., Mentias, A., Barakat, A., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.042 · Cited by 140
Self-citationDeVore, A. D., Braunwald, E., Morrow, D. A., Duffy, C. I., Ambrosy, A. P., Chakraborty, H., McCague, K., Rocha, R., Velazquez, E. J., & for the PIONEER-HF Investigators (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4665 · Cited by 87
Lam, P. H., Gupta, N., Dooley, D. J., Singh, S., Deedwania, P., Zile, M. R., Bhatt, D. L., Morgan, C. J., Pitt, B., Fonarow, G. C., et al. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.07.008 · Cited by 36
Cited by
Chitosan-Based Biomaterials for Tissue Regeneration
Kim, Y., Zharkinbekov, Z., Raziyeva, K., Tabyldiyeva, L., Berikova, K., Zhumagul, D., Temirkhanova, K., & Saparov, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030807 · Cited by 264
Molecular Mechanisms of Mitochondrial Quality Control in Ischemic Cardiomyopathy
Chang, X., Liu, R., Li, R., Peng, Y., Zhu, P., & Zhou, H. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.76223 · Cited by 185
“coronary stenosis and myocardial ischemia are coronary atherosclerosis, arterial thrombosis, vascular inflammation/injury and coronary microvascular injury/abnormal coronary artery structure [8, 9].”
BackgroundLee, Y.-B., Han, K., Kim, B., Lee, S.-E., Jun, J. E., Ahn, J., Kim, G., Jin, S.-M., & Kim, J. H. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0953-7 · Cited by 131
Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD
Poznyak, A. V., Bharadwaj, D., Prasad, G., Grechko, A. V., Sazonova, M. A., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136702 · Cited by 142
“Although, the LIFE (the Losartan Intervention for Endpoint Reduction in Hypertension Study) trial demonstrated a marked decrease of stroke risk, but not of myocardial infarction in hypertensive patients with left ventricular hypertrophy who received losartan in comparison to a patient who received atenolol.”
BackgroundInfluentialZhang, H., Xue, Y., Pan, T., Zhu, X., Chong, H., Xu, C., Fan, F., Cao, H., Zhang, B., Pan, J., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056264 · Cited by 44
Metadata
- Authors
- Elgendy, I. Y., Mahtta, D., & Pepine, C. J.
- Venue
- Circulation Research
- Published
- 2019-05-24
- Volume
- 124
- Issue
- 11
- Pages
- 1520-1535
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2945043974
- Cited by
- 176
- References
- 48
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.